Comparative Pharmacology
Head-to-head clinical analysis: RISPERDAL versus VRAYLAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RISPERDAL versus VRAYLAR.
RISPERDAL vs VRAYLAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Risperidone is a benzisoxazole atypical antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors. It also blocks alpha1-adrenergic, alpha2-adrenergic, and histamine H1 receptors.
Cariprazine is a partial agonist at dopamine D2 and D3 receptors and serotonin 5-HT1A receptors, and an antagonist at 5-HT2A and 5-HT2B receptors. Its antipsychotic activity is primarily mediated via D2 and D3 receptor partial agonism.
2-8 mg orally once daily or divided twice daily; maximum 16 mg/day
1.5 mg orally once daily with food, then titrate to 3 mg on day 4, then to 6 mg on day 8; maximum dose 6 mg/day.
None Documented
None Documented
20 hours (parent drug), 23 hours (active metabolite 9-hydroxyrisperidone). Steady state reached in 5-6 days. Extended in elderly and hepatic/renal impairment.
The terminal elimination half-life of cariprazine is 2-4 days, and for its active metabolites (desmethylcariprazine and didesmethylcariprazine) it is 1-3 weeks. This long half-life results in steady-state concentrations being reached after 3-4 weeks of daily dosing, contributing to prolonged clinical effects and a need for slow titration.
Renal: 70% (30% as unchanged drug, 40% as metabolites), Fecal/Biliary: 14%
Cariprazine and its active metabolites are primarily eliminated via hepatic metabolism and subsequent biliary/fecal excretion. Approximately 20% of the dose is recovered in urine, mainly as inactive metabolites, while about 80% is recovered in feces, largely as unchanged cariprazine and its active metabolites.
Category C
Category C
Atypical Antipsychotic
Atypical Antipsychotic